{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-24-000104","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.587078+00:00","generated_at":"2026-05-31T15:04:18.584647+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share","bullets":["Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).","Gross margin 74.7%, down 168 bps YoY due to mix and product costs; operating loss $7.2M vs $4.1M loss.","Net loss per share $0.17 vs $0.11; adjusted EBITDA $7.8M, down $0.2M vs Q2 2023.","Generated positive cash flow of $8.1M during the quarter.","CEO cited strong growth from pain management and AtriClip franchises; advancing LeAAPS trial and new product launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-24-000104","json":"https://secwatch.observer/filing/0001323885-24-000104.json","markdown":"https://secwatch.observer/filing/0001323885-24-000104.md","text":"https://secwatch.observer/filing/0001323885-24-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000104/0001323885-24-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388524000104/atrc-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:04:18.584647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}